ArticleSubstance abuse2015
Buprenorphine Treatment for Probationers and Parolees.
Article in Substance abuse, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Pharmacotherapy for opioid addiction in community corrections.International review of psychiatry (Abingdon, England) · 2018Pooled it
- Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?Journal of substance abuse treatment · 2018Trial
- Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.Addiction (Abingdon, England) · 2017Trial
- Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.The New England journal of medicine · 2016Trial
- Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.Contemporary clinical trials · 2015Trial
- Rationale and design of a three-arm randomized clinical trial to improve drug use and retention in care of people with opioid use disorder on buprenorphine: OVERCOME II study.Contemporary clinical trials · 2026Article
- Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners.Health & justice · 2024Article
- Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.Journal of substance use and addiction treatment · 2023Article
- Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine.Substance abuse · 2022Article
- Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study.Contemporary clinical trials communications · 2022Article
- Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol.Journal of substance abuse treatment · 2021Article
- Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.Drug and alcohol dependence · 2021Article
- Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System.Infectious disease clinics of North America · 2020Review
- Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.Addiction science & clinical practice · 2020Article
- Italian psychiatry.International review of psychiatry (Abingdon, England) · 2018Article
- Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices.Substance abuse · 2016Article
- Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.Substance abuseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPharmacotherapy studies involving buprenorphine have rarely been conducted with U.S. community corrections populations. This is one of the first reports of buprenorphine treatment outcomes of adult opioid-dependent probationers and parolees.
methodsThis longitudinal study examined the 3-month treatment outcomes for a sample of probation and parole clients (N = 64) who received community-based buprenorphine treatment.
resultsApproximately two thirds of the sample (67%) were still in treatment at 3 months post baseline. Furthermore, there was a significant decline in the number of self-reported heroin use days and crime days from baseline to 3 months post baseline. Although there was not a significant reduction in reincarcerations, there was no evidence that they had increased.
conclusionsGiven that buprenorphine is approved by the Food and Drug Administration (FDA) as a safe, effective treatment for opioid use disorders, individuals on parole or probation should have the opportunity to benefit from it through community-based programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.